Arbutus生物制药 ABUS 深 沪
交易中 09-23 12:01:08 美东时间
4.455
+0.025
+0.56%
华盛通- 最 高4.555
- 今 开4.50
- 成交量 38.73万股
- 最 低 4.4347
- 昨 收 4.43
- 总市值 8.55亿
- 52周最高 5.10
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 2.705
- 委 比 -53.19%
- 总股本 1.92亿
- 历史最高 31.48
- 量 比 0.85
- 振 幅 2.72%
- 历史最低 0.821
- 每 手 1
- 风险率 0.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arbutus Biopharma’s Patent Ruling in Pfizer Lawsuit
The latest update is out from Arbutus Biopharma ( ($ABUS) ). On September 9, 20...
09-10 21:30
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target
Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.
08-11 19:22
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
Assembly Biosciences announced positive interim results from a Phase 1b study of ABI-5366, a long-acting HSV helicase-primase inhibitor, in participants with recurrent genital herpes. The 350 mg weekly oral dose showed 94% reduction in HSV-2 shedding rate, 98% reduction in high viral load shedding rate, and 94% reduction in genital lesion rate compared to placebo, all statistically significant. The drug demonstrated favorable safety and tolerabil...
08-08 12:00
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics granted 14,000 restricted stock units to two new hires under its 2022 Inducement Plan, vesting over four years. The company, focused on immune-mediated dermatology, aims to innovate treatments for skin diseases.
07-03 20:00
Arbutus Biopharma Ends Partnership with Qilu Pharmaceutical
The latest update is out from Arbutus Biopharma ( ($ABUS) ). On June 20, 2025, ...
06-25 19:59
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Arbutus and Qilu Pharmaceutical have mutually terminated their 2021 strategic partnership for imdusiran in Greater China, with Arbutus regaining global rights. Arbutus launched a Scientific Advisory Board with leading experts in chronic hepatitis B to guide its cHBV pipeline evaluation. Imdusiran has achieved functional cure in 8 patients across Phase 2a trials.
06-25 11:30
Arbutus Biopharma Q1 EPS $(0.13) Misses $(0.10) Estimate, Sales $1.76M Miss $1.78M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 30 percent. This is a 30 percent decrease over losses of $(0.10) per share from the
05-14 19:36
Arbutus's Imdusiran Plus VTP-300 And Low-Dose Nivolumab Achieve HBsAg Loss And Seroconversion In cHBV Patients, New Phase 2a Data Reveal At EASL 2025
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumabIn a Phase 1a/1b clinical trial,
05-07 15:10
超百款新车、千家企业齐聚“上海滩”！2025上海车展掀起“智电”浪潮 这场展会还藏着未来发展“生死密码”
每经记者 黄辛旭每经编辑 孙磊 2025上海车展，为竞争激烈且复杂的国内车市指明了方向。 4月23日，第二十一...
04-23 22:59
